Preview Mode Links will not work in preview mode

Clinical Literature Summaries presented by InpharmD™ (S3)


Jan 25, 2021

A prospective, randomized, open-label trial performed to evaluate whether continuation of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) is beneficial or harmful in patients who are admitted to hospital with COVID-19.